As the threat of COVID-19 subsides, scientists are working to make sense of the information that was gathered during the pandemic. Caroline Baumal, MD, asks M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, to tackle two papers that analyze data collected during this time. First, they address the strengths and limits of a paper from the infectious disease realm that used history of AMD as a marker for complement inhibition in patients with COVID-19. Then, they parse the details of an article reviewing how real-world high-frequency patients with wet AMD fared when treatment intervals were increased during the height of the pandemic.

This editorially independent podcast is supported with advertising.